Aisa Pharma has initiated the second part of its RECONNOITER Phase 2 study, which will evaluate Profervia®, an oral calcium-channel antagonist, in patients with systemic sclerosis and Raynaud's phenomenon. The double-blind, placebo-controlled, randomized, prospective crossover study is expected to last approximately 10 months. Aisa also presented positive safety and efficacy data from the Phase 2a RECONNOITER study at EULAR 2023 in Milan. The results showed that Profervia® had a greater effect on Raynaud's attack frequency and reduced SSc disease severity compared with placebo.
Aisa Pharma is a private biopharmaceutical company based in Boston that is developing Profervia® for use in patients with SSc-RP. Systemic sclerosis affects almost all patients with Raynaud's, and new treatments are urgently needed given the high morbidity and burden of the disease.
Keywords: Aisa Pharma, Profervia®, Phase 2b Study, Raynaud's Phenomenon, Systemic Sclerosis
Aisa Pharma has started Part 2 of its